Form 4 for CTOR CITIUS ONCOLOGY, INC.
Accepted 2025-08-07 00:00:00 ET · period of report 2025-07-28 · accession 0001213900-25-073136 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-07 | 2025-07-28 | CTOR | Mayersohn Joel David | Dir | J - Other | $0.00 | +21.2K | 21.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-28 | J | A | 21,228 | $0.00 | 21,228 | D | — | — | (F1) The shares were acquired through a distribution in kind to limited partners of 10XYZ Holdings, which was the Sponsor of TenX Keane Acquisition ("TenX"), the legacy entity of Citius Oncology, Inc. |